Advanced gene therapies have been at the forefront of medical science for many years, offering the promise of potential cures for a wide range of diseases. As recent FDA approvals have made these therapies a reality, the unprecedented costs associated with them have raised significant concerns to the health insurance industry.
This whitepaper will give an overview of the financial challenges that these treatments pose to health plans, employers, and other self-funded entities, and how new insurance offerings can ensure access to therapies, while driving down costs and protecting payers from significantly adverse situations.
Fill out the form to view the latest in mitigating gene therapy risk.
"*" indicates required fields